+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies



The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies



Pregnancy Hypertension 2018



A sFlt-1/PlGF ratio of ≤38 has been reported to predict the absence of preeclampsia (PE) in singleton pregnancies. We evaluated whether a sFlt-1/PlGF ratio of ≤38 could be used to predict the absence of PE in twin pregnancies and maternal and fetal/neonatal complications. This is a secondary analysis of a prospective multicenter cohort study that enrolled women with suspected or confirmed PE with the aim of evaluating the use of the sFlt-1, PlGF and their ratio to predict maternal and fetal/neonatal complications. Twin and singleton pregnancies with clinically suspected or confirmed PE were matched for gestational age and parity. Blood samples were drawn at time of study entry, but serum values of sFlt-1 and PlGF and their ratio were determined postpartum. Twenty-one women with twin and 21 with singleton gestations were included at a median gestational age of 30 weeks. At inclusion PE was diagnosed in 13 twin and 15 singleton pregnancies. In comparison to singleton control pregnancies, twin controls had a significantly higher sFlt-1 (6377 vs. 1732 pg/ml, p = 0.008), a higher sFlt-1/PlGF ratio 26 vs. 3 p = 0.361) and a lower PlGF (228 vs. 440 pg/ml p = 0.479). Compared to singleton preeclamptic pregnancies values of sFlt-1 (9134 vs. 8625 pg/ml) did not differ, whereas values of PlGF (185 vs. 33 pg/ml, p < 0.001) were higher and values of the ratio (49 vs. 158, p = 0.002) were lower in preeclamptic twin pregnancies. All preeclamptic patients with a singleton pregnancy had a ratio >38, but only 5 of the 13 patients with a preeclamptic twin pregnancy. Conversely, the ratio was ≤38 in 5 of the 6 control singleton, but in only 4 of the 8 control twin pregnancies. When classified according to a ratio ≤38 or >38 at inclusion, maternal complications occurred more frequently in patients with a ratio >38 both in singleton and twin pregnancies. In singleton pregnancies fetal/neonatal complications, except one admission to NICU, only occurred in patients with a ratio >38. In twin pregnancies fetal/neonatal complications occurred equally frequent in women with a ratio ≤38 or >38. Serum sFlt-1 levels are considerably higher in twin than in singleton control gestations. A sFlt-1/PlGF ratio of ≤38 to predict short-term absence of PE is not applicable to twin pregnancies in predicting either the absence of PE or the absence of adverse pregnancy outcomes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065603684

Download citation: RISBibTeXText

PMID: 29678353

DOI: 10.1016/j.preghy.2018.03.014


Related references

Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy. Pregnancy Hypertension 12: 124-128, 2018

Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies. Ultrasound in Obstetrics and Gynecology 45(3): 286-293, 2015

Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF. Ultrasound in Obstetrics and Gynecology 49(2): 201-208, 2016

Urinary sFlt-1 and PlGF levels are strongly correlated to serum sFlt-1/PlGF ratio and serum PlGF in women with preeclampsia. Pregnancy Hypertension 12: 82-83, 2018

sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics. Medicina 52(6): 349-353, 2016

Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/ PlGF Ratio in Singleton Pregnancies. Fetal Diagnosis and Therapy 43(2): 81-89, 2017

Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. New England Journal of Medicine 374(1): 13-22, 2016

OP17.04: Predictive value of serial sFlt-1, PlGF and sFlt-1/PlGF ratio measurement in predicting the development of placental syndrome in women at high risk: a pilot study. Ultrasound in Obstetrics & Gynecology 50: 103-103, 2017

P28. Predictive value of the sFlt-1/PlGF ratio in pregnancies at risk for hypertensive disorders. Pregnancy Hypertension 1(3-4): 285-286, 2011

Comparison of mean platelet volume (Mpv) and sFlt-1/PlGf ratio as predictive markers for preeclampsia. The Journal of Maternal-Fetal & Neonatal Medicine, 2019

Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy. Bmc Research Notes 8: 534, 2016

Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia. Zhonghua Fu Chan Ke Za Zhi 49(1): 22-25, 2014

Short-Term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGf (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia. Hypertension 74(1): 164-172, 2019

Comparison of maternal serum PlGF and sFlt-1 between pregnancies with and without fetal hemoglobin Bart's disease. Prenatal Diagnosis 33(13): 1272-1275, 2014

A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertension in Pregnancy 35(3): 295-305, 2017